Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Łódź. Najwięcej badań dotyczy: rak płuca, chłoniak, nieswoiste zapalenia jelit, cukrzyca.
532 badania: 501 rekrutuje, 31 wkrótce zacznie.
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
+3A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
+10A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
+6Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer
LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
+15A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed…
+3Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or…
+14A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
+18A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
+22Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
+2Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
+1A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
+12Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
+15Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
+20Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
+6Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
+4A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal…
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care…
+21A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC)…
+28Long-term Safety and Tolerability of BHV-7000
+19A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
+39A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
+22Study of Olverembatinib (HQP1351) in Patients With CML-CP
+8A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
+17Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
+2Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 3 października 2026.